Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors
Molecules · 2023
DOI: 10.3390/molecules28114346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Simin Ye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity …. Hauptthemen laut MEDLINE: Antidepressive Agents, Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Project of China, SJTU Global Strategic Partnership Fund.
Abstract (Originalsprache)
Depression, a mental disorder that plagues the world, is a burden on many families. There is a great need for new, fast-acting antidepressants to be developed. N-methyl-D-aspartic acid (NMDA) is an ionotropic glutamate receptor that plays an important role in learning and memory processes and its TMD region is considered as a potential target to treat depression. However, due to the unclear binding sites and pathways, the mechanism of drug binding lacks basic explanation, which brings great complexity to the development of new drugs. In this study, we investigated the binding affinity and mechanisms of an FDA-approved antidepressant (S-ketamine) and seven potential antidepressants (R-ketamine, memantine, lanicemine, dextromethorphan, Ro 25-6981, ifenprodil, and traxoprodil) targeting the NMDA receptor by ligand–protein docking and molecular dynamics simulations. The results indicated that Ro 25-6981 has the strongest binding affinity to the TMD region of the NMDA receptor among the eight selected drugs, suggesting its potential effective inhibitory effect. We also calculated the critical binding-site residues at the active site and found that residues Leu124 and Met63 contributed the most to the binding energy by decomposing the free energy contributions on a per-residue basis. We further compared S-ketamine and its chiral molecule, R-ketamine, and found that R-ketamine had a stronger binding capacity to the NMDA receptor. This study provides a computational reference for the treatment of depression targeting NMDA receptors, and the proposed results will provide potential strategies for further antidepressant development and is a useful resource for the future discovery of fast-acting antidepressant candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 2…
- Key Laboratory for Thin Film and Microfabrication of Ministry of Education, Department of Micro/Nano-Electronics, Shanghai Jiao Tong University, Shanghai 200240, China.
ORCID-Profile: Yanqiang Han, Jinjin Li
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Project of China
- SJTU Global Strategic Partnership Fund
- National Key R&D Program of China
- the National Key R&D Program of China
- the National Natural Science Foundation of China
- the Shanghai Science and Technology Project of China
- the Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Ye, S., Han, Y., Wei, Z., & Li, J. (2023). Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors. Molecules. https://doi.org/10.3390/molecules28114346
Vancouver
Ye S, Han Y, Wei Z, Li J. Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors. Molecules. 2023. doi:10.3390/molecules28114346
BibTeX
@article{Ye2023,
author = {Ye, Simin and Han, Yanqiang and Wei, Zhiyun and Li, Jinjin},
title = {Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28114346}
}
EUVIMED